Independent Research
HIMS Analysis
10 pieces of research on Hims & Hers Health, Inc.. We find the signal management buried in the earnings call.
HIMS Rally Hides Insider Selling After Record EPS Misses
HIMS stock hit a 2026 high after securing a $400 million JPMorgan working capital facility, yet five C-suite executives unloaded $3.61 million in shares during …
Read analysis →Hims & Hers Surges on Novo Nordisk Deal, Insiders Sell
Hims & Hers Health stock surged 14% to what news sources called its best single day ever on reports of a Novo Nordisk partnership, incinerating $546 million in …
Read analysis →Hims & Hers Director Bets $1.2M as GLP-1 Battle Heats Up
Director David B Wells purchased $1.17 million in HIMS stock on May 26, days after a 13% earnings-driven drop that Reuters tied to the company's branded weight-…
Read analysis →Hims & Hers Health Tumbles on Q2 Miss With 31.9% Float Short
Hims & Hers Health missed Q2 bottom-line consensus estimates as losses widened more than expected, sending shares lower despite a guidance raise for the next pe…
Read analysis →Hims & Hers Stock Falls 9% After $350 Million Leveraged Acquisition
Hims & Hers upsized a debt raise to $350M to fund the Eucalyptus acquisition alongside an AI initiative, triggering a ~9% share decline as investors questioned …
Read analysis →